Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Metrics: PDF 1484 views | HTML 2091 views | ?
Liang Xia1,*, Bin Wu1,*, Zhiquan Fu2, Fang Feng1, Enqi Qiao1, Qinglin Li1, Caixing Sun1, Minghua Ge1
1Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China
2Shanghai Hospital of Integrated Traditional and Western Medicine, Hongkou District, Shanghai, China
*These authors have contributed equally to this work
Qinglin Li, e-mail: firstname.lastname@example.org
Caixing Sun, e-mail: email@example.com
Minghua Ge, e-mail: firstname.lastname@example.org
Keywords: IDH mutations, prognosis, glioma
Received: December 16, 2014 Accepted: July 06, 2015 Published: July 16, 2015
Background: IDH (Isocitrate dehydrogenase) mutations occur frequently in gliomas, but their prognostic impact has not been fully assessed. We performed a meta-analysis of the association between IDH mutations and survival in gliomas.
Methods: Pubmed and EMBASE databases were searched for studies reporting IDH mutations (IHD1/2 and IDH1) and survival in gliomas. The primary outcome was overall survival (OS); the secondary outcome was progression-free survival (PFS). Hazard ratios (HR) with 95% confidence interval (CI) were determined using the Mantel-Haenszel random-effect modeling. Funnel plot and Egger’s test were conducted to examine the risk of publication bias.
Results: Fifty-five studies (9487 patients) were included in the analysis. Fifty-four and twenty-seven studies investigated the association between IDH1/2 mutations and OS/PFS respectively in patients with glioma. The results showed that patients possessing an IDH1/2 mutation had significant advantages in OS (HR = 0.39, 95%CI: 0.34–0.45; P < 0.001) and PFS (HR = 0.42, 95% CI: 0.35–0.51; P < 0.001). Subgroup analysis showed a consistent result with pooled analysis, and patients with glioma of WHO grade III or II-III had better outcomes.
Conclusions: These findings provide further indication that patients with glioma harboring IDH mutations have improved OS and PFS, especially for patients with WHO grade III and grade II-III.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.